We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
from PART II - CLINICAL RESEARCH
Published online by Cambridge University Press: 05 June 2012
Appropriate surgical resection of the primary tumor and involved locoregional lymph nodes remains the mainstay of therapy for patients with thyroid cancer. Depending on the specific tumor histology and the estimated risk of recurrence/death, additional adjuvant therapies, such as radioactive iodine, levothyroxine suppression, or external beam irradiation, are often recommended. With these treatments, most patients with thyroid cancer can expect more than 90 percent disease-specific survival rates over a thirty-year follow-up period.
However, there is a subset of thyroid cancer patients with RAI refractory disease that can have survival rates as low as 30 percent over three to five years. Unfortunately, radioactive iodine (RAI)-refractory metastatic thyroid cancer has proven to be quite resistant to traditional cytotoxic chemotherapy. However, recent advances in our understanding of the molecular biology of thyroid cancer coupled with the availability of relatively specific tyrosine kinase inhibitors has dramatically changed our approach to the management of RAI-refractory, structurally progressive thyroid cancer.
In this chapter we review the initial presentation, risk stratification, and therapy of thyroid cancer with a specific emphasis on novel systemic therapy options for patients with structurally progressive disease that cannot be controlled with either local measures or RAI therapy.
PATTERNS OF METASTATIC SPREAD, ORGAN SPECIFICITY, TIMING OF RECURRENT DISEASE, AND COMPLICATIONS CONFRONTED WITH METASTASIS
Thyroid cancers arise either from thyroid follicular cells (papillary, follicular, and anaplastic thyroid cancers) or from other cells within the thyroid gland, such as lymphocytes (primary thyroid lymphoma) or neuroendocrine c-cells (medullary thyroid cancer).
To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Find out more about the Kindle Personal Document Service.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.
